BRPI0411794A - processos para a preparação de derivados de 1-[(benzoimidazol-1-il)quinolin-8-il]piperidin-4-ilamina - Google Patents

processos para a preparação de derivados de 1-[(benzoimidazol-1-il)quinolin-8-il]piperidin-4-ilamina

Info

Publication number
BRPI0411794A
BRPI0411794A BRPI0411794-8A BRPI0411794A BRPI0411794A BR PI0411794 A BRPI0411794 A BR PI0411794A BR PI0411794 A BRPI0411794 A BR PI0411794A BR PI0411794 A BRPI0411794 A BR PI0411794A
Authority
BR
Brazil
Prior art keywords
benzoimidazol
quinolin
piperidin
processes
preparation
Prior art date
Application number
BRPI0411794-8A
Other languages
English (en)
Inventor
Norma Jacqueline Tom
David Harold Brown Ripin
Michael James Castaldi
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0411794A publication Critical patent/BRPI0411794A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)

Abstract

"PROCESSOS PARA A PREPARAçãO DE DERIVADOS DE 1-¢(BENZOIMIDAZOL-1-IL)QUINOLIN-8-IL!PIPERIDIN-4-ILAMINA" . A presente invenção refere-se a um processo para a preparação de um composto de fórmula (I) ou um sal, pró-fármaco, hidrato ou solvato farmaceuticamente aceitável do mesmo, em que R¬ 1¬, R¬ 2¬, R¬ 3¬ e R¬ 4¬ são como aqui definido. O composto de fórmula (I) é útil no tratamento do crescimento celular anormal, tal como câncer, em mamíferos.
BRPI0411794-8A 2003-06-24 2004-06-14 processos para a preparação de derivados de 1-[(benzoimidazol-1-il)quinolin-8-il]piperidin-4-ilamina BRPI0411794A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48217603P 2003-06-24 2003-06-24
PCT/IB2004/001983 WO2004113322A1 (en) 2003-06-24 2004-06-14 Processes for the preparation of 1-[(benzoimidazole-1yl) quinolin-8-yl] piperidin-4-ylamine derivatives

Publications (1)

Publication Number Publication Date
BRPI0411794A true BRPI0411794A (pt) 2006-08-08

Family

ID=33539339

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411794-8A BRPI0411794A (pt) 2003-06-24 2004-06-14 processos para a preparação de derivados de 1-[(benzoimidazol-1-il)quinolin-8-il]piperidin-4-ilamina

Country Status (24)

Country Link
US (2) US7183414B2 (pt)
EP (1) EP1641780B1 (pt)
JP (1) JP2007516168A (pt)
KR (2) KR20070092333A (pt)
CN (1) CN100404530C (pt)
AR (1) AR044849A1 (pt)
AT (1) ATE414077T1 (pt)
AU (1) AU2004249511B2 (pt)
BR (1) BRPI0411794A (pt)
CA (1) CA2529032C (pt)
CL (1) CL2004001470A1 (pt)
CO (1) CO5650165A2 (pt)
DE (1) DE602004017731D1 (pt)
DK (1) DK1641780T3 (pt)
ES (1) ES2315663T3 (pt)
IL (1) IL172064A (pt)
MX (1) MXPA05014203A (pt)
NO (1) NO20060376L (pt)
NZ (2) NZ543714A (pt)
RU (1) RU2323214C2 (pt)
SG (1) SG161745A1 (pt)
TW (1) TWI294425B (pt)
WO (1) WO2004113322A1 (pt)
ZA (1) ZA200509253B (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
CA2582479C (en) * 2004-10-07 2011-07-12 Pfizer Products Inc. Benzoimidazole derivatives useful as antiproliferative agents
BRPI0610514A2 (pt) * 2005-04-05 2016-11-16 Pharmacopeia Inc composto, composição farmacêutica, e, método de tratamento de um distúrbio
US7504513B2 (en) 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
JP2012512223A (ja) 2008-12-18 2012-05-31 エフ．ホフマン−ラ ロシュ アーゲー チアゾリル−ベンズイミダゾール類
CN101993416B (zh) * 2009-08-27 2013-09-11 中国科学院上海药物研究所 喹啉类化合物、其制备方法、包含该化合物的药物组合物及该化合物的用途
JP6407504B2 (ja) 2012-09-21 2018-10-17 アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法
US10835525B2 (en) 2012-09-26 2020-11-17 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
US11642340B2 (en) 2012-09-26 2023-05-09 Arog Pharmaceuticals, Inc. Method of inhibiting mutant C-KIT
TWI599356B (zh) 2012-09-26 2017-09-21 安羅格製藥有限責任公司 抑制突變型ｃ－ｋｉｔ的方法
BR112015016282A2 (pt) 2013-01-07 2017-07-11 Arog Pharmaceuticals, Inc. crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
US10463658B2 (en) 2013-10-25 2019-11-05 Videra Pharmaceuticals, Llc Method of inhibiting FLT3 kinase
US12534764B2 (en) 2016-11-02 2026-01-27 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
US12662706B2 (en) 2016-11-02 2026-06-23 Arog Pharmaceuticals, Inc. Crenolanib for treating FLT3 mutated proliferative disorders associated mutations
KR20180074792A (ko) 2016-11-02 2018-07-03 아로그 파마슈티칼스, 인코퍼레이티드 돌연변이 연관된 flt3 돌연변이된 증식성 장애를 치료하기 위한 크레노라닙
CN107382984B (zh) * 2017-08-24 2020-07-10 扬州市三药制药有限公司 一种治疗白血病药物的制备方法
CN107382983B (zh) * 2017-08-24 2020-08-07 扬州市三药制药有限公司 一种治疗白血病药物的合成方法
CN110840893A (zh) 2018-12-13 2020-02-28 安罗格制药有限责任公司 含克莱拉尼的药物组合物及其用途
CN109678849A (zh) * 2019-01-16 2019-04-26 北京悦康科创医药科技股份有限公司 一种抗癌药物的制备方法
US11471451B2 (en) 2019-08-19 2022-10-18 Arog Pharmaceuticals, Inc. Uses of crenolanib
CN117447376B (zh) * 2019-12-09 2026-06-09 苏州恩华生物医药科技有限公司 连双环结构sigma-1受体抑制剂
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
WO2022019998A1 (en) 2020-07-20 2022-01-27 Arog Pharmaceuticals, Inc. Crystal forms of crenolanib and methods of use thereof
AU2021320860A1 (en) 2020-08-05 2023-02-23 The General Hospital Corporation Salt inducible kinase inhibitors
US20220079934A1 (en) * 2020-09-17 2022-03-17 Arog Pharmaceuticals, Inc. Crenolanib for treating pain
US11524006B2 (en) 2020-09-17 2022-12-13 Arog Pharmaceuticals, Inc. Crenolanib for treating TRK kinase associated proliferative disorders
WO2022090547A1 (en) 2020-10-30 2022-05-05 Dsm Ip Assets B.V. Production of carotenoids by fermentation
US11969420B2 (en) 2020-10-30 2024-04-30 Arog Pharmaceuticals, Inc. Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
CN113683594B (zh) * 2021-09-07 2022-12-27 曲靖师范学院 一种喹啉-苯并咪唑盐类化合物及其合成方法和应用
JP2023063189A (ja) 2021-10-22 2023-05-09 アログ・ファーマシューティカルズ・インコーポレイテッド 以前の治療に対して再発性／不応性のｆｌｔ３突然変異増殖性障害を治療するためのクレノラニブ

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897401A (en) * 1987-06-19 1990-01-30 Janssen Pharmaceutical N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives useful in treating allergic diseases
US5478832A (en) * 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
WO1998038156A1 (en) * 1997-02-27 1998-09-03 Takeda Chemical Industries, Ltd. Amine compounds, their production and use as amyloid-beta production inhibitors
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
JP4554135B2 (ja) * 1999-12-10 2010-09-29 富士フイルム株式会社 インクジェットヘッドおよび印刷装置
US6515179B2 (en) * 2000-09-14 2003-02-04 Kaneka Corporation Process for the removal of nitrobenzenesulfonyl
PA8580301A1 (es) * 2002-08-28 2005-05-24 Pfizer Prod Inc Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos

Also Published As

Publication number Publication date
KR20060012033A (ko) 2006-02-06
NO20060376L (no) 2006-01-24
CA2529032A1 (en) 2004-12-29
AU2004249511B2 (en) 2011-01-20
IL172064A (en) 2011-01-31
HK1089170A1 (en) 2006-11-24
NZ543714A (en) 2009-06-26
AU2004249511A1 (en) 2004-12-29
RU2323214C2 (ru) 2008-04-27
DK1641780T3 (da) 2009-02-02
ZA200509253B (en) 2007-01-31
KR20070092333A (ko) 2007-09-12
CO5650165A2 (es) 2006-06-30
ES2315663T3 (es) 2009-04-01
RU2005138367A (ru) 2006-08-10
SG161745A1 (en) 2010-06-29
CN1809556A (zh) 2006-07-26
CN100404530C (zh) 2008-07-23
EP1641780A1 (en) 2006-04-05
AR044849A1 (es) 2005-10-05
DE602004017731D1 (de) 2008-12-24
MXPA05014203A (es) 2006-02-24
CA2529032C (en) 2009-12-22
WO2004113322A1 (en) 2004-12-29
US20070088032A1 (en) 2007-04-19
TW200517393A (en) 2005-06-01
NZ571898A (en) 2010-01-29
CL2004001470A1 (es) 2005-05-13
TWI294425B (en) 2008-03-11
ATE414077T1 (de) 2008-11-15
US7183414B2 (en) 2007-02-27
KR100787649B1 (ko) 2007-12-21
EP1641780B1 (en) 2008-11-12
US20050020625A1 (en) 2005-01-27
JP2007516168A (ja) 2007-06-21

Similar Documents

Publication Publication Date Title
MXPA05014203A (es) Procedimientos para la preparacion de derivados de benzoimidazol.
BR0313942A (pt) Derivados de benzimidazol úteis como agentes antiproliferativos
PL374191A1 (en) 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
BRPI0510980A (pt) derivados de pirimidina para o tratamento do crescimento anormal de células
BR0317435A (pt) Derivados de pirimidina para o tratamento do crescimento celular anormal
BR0317524A (pt) Compostos derivados de pirrolopirimidina, composição farmacêutica, processo para as suas preparações e respectivo uso
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
GEP20104906B (en) Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
UA89123C2 (ru) Производные пиримидина для лечения абнормального роста клеток
CA2478374A1 (en) N3 alkylated benzimidazole derivatives as mek inhibitors
TW200833693A (en) Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
BR0009297A (pt) Composto, processo para produzir o mesmo,composição farmacêutica, método paraantagonizar hormÈnio de liberação degonadotropina em um mamìfero, e, uso de umcomposto
YU30702A (sh) Novi derivati benzoimidazola, korisni agensi protiv proliferacije
NZ543661A (en) Pyrazolo-quinazoline derivatives having antitumor activity and process for their preparation
BRPI0916356A2 (pt)
BR0213040A (pt) Composto, processo para preparar um composto, e, método de tratar doenças
UA94719C2 (ru) Применение производного имидазол-2-карбоновой кислоты для лечения или профилактики гематологической злокачественной опухоли
WO2005054179A3 (en) Hydroxamic acid esters and pharmaceutical use thereof
BR9908125A (pt) Composto, composto dimérico, composição farmacêutica, uso do composto, processo compreendendo inibir células de câncer, e, processo terapêutico
UY28255A1 (es) Formas de dosificacion y procedimientos de tratamiento que usan inhibidores del veger
MX2007013624A (es) Inhibidores de proteina cinasa.
UA96304C2 (en) 2-METHYLMORPHOLINE PYRIDO-, PYRAZO- AND PYRIMIDO-PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2007034279A3 (en) C3a antagonists and pharmaceutical compositions thereof
BR0317433A (pt) Derivados bicìclicos para o tratamento do crescimento celular anormal
BR0312470A (pt) Composto, uso do mesmo, composição farmacêutica, método de tratar e/ou prevenir câncer, e, processo para preparar o composto

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2310 DE 14-04-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.